Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: A single United Arab Emirates center experience

European Journal of Internal Medicine

Volumn 22, Issue 6, 2011, Pages 582-586

  Giguere, A ^a   Anas, A ^a   Nasser, T ^a   Hassan, M H ^a   Ahmed, U ^a   Beejay, N ^a   Nouh, M ^a   Khalowf, M ^a   Saleh, A ^a   Khan, A ^a   Attia, M ^b   El Azab, G ^c  

^a SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^b SAAD Hospital   (Saudi Arabia)

^c MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Adverse effects; End stage renal disease; Hemodialysis; Hepatitis C; Peginterferon; Ribavirin; Treatment

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HEPATITIS C; HUMAN; LOW DRUG DOSE; MALE; NEUTROPENIA; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; UNITED ARAB EMIRATES;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; UNITED ARAB EMIRATES;

EID: 80855138763     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2011.05.008     Document Type: Article

References (38)

1. P.R. Patel, N.D. Thompson, A.J. Kallen, and M.J. Arduino Epidemiology, surveillance and prevention of hepatitis C virus infection in hemodialysis patients Am J Kidney Dis 56 2010 371 378
2. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
3. D. Marcelli, D. Stannard, F. Conte, P.J. Held, F. Locatelli, and F.K. Port ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States Kidney Int 50 1996 1013 1018 (Pubitemid 26302692)
4. P. Maisonneuve, L. Agodoa, R. Gellert, J.H. Stewart, G. Buccianti, and A.B. Lowenfels Cancer in patients on dialysis for end-stage renal disease: an international collaborative study Lancet 354 1999 93 99 (Pubitemid 29313142)
5. E. Nakayama, T. Akiba, F. Marumo, and C. Sato Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy J Am Soc Nephrol 11 2000 1896 1902
6. F. Fabrizi, F.F. Poordad, and P. Martin Hepatitis C infection and the patient with end stage renal disease Hepatology 36 2002 3 10 (Pubitemid 34700756)
7. V. Bocci, A. Pacini, M. Muscettola, L. Paulesu, G.P. Pessina, and M. Santiano Renal filtration, absorption and catabolism of human alpha interferon J Interferon Res 1 1981 347 352 (Pubitemid 12105785)
8. T. Bino, Z. Madar, A. Gertler, and H. Rosenberg The kidney is the main site of interferon degradation J Interferon Res 2 1982 301 308 (Pubitemid 13138655)
9. T.H. Kramer, G.G. Gaar, C.G. Ray, L. Minnich, J.G. Copeland, and J.D. Connor Hemodialysis clearance of intravenously administered ribavirin Antimicrob Agents Chemother 34 1990 489 490 (Pubitemid 20068680)
10. P. Glue The clinical pharmacology of ribavirin Semin Liver Dis 19 Suppl. 1 1999 17 24 (Pubitemid 29220816)
11. M. Berenguer Treatment of chronic hepatitis C in hemodialysis patient Hepatology 48 2008 1690 1699
12. L. Rostaing, E. Chatelut, J.L. Payen, J. Izopet, C. Thalamas, and H. Ton-That Pharmacokinetics of alpha IFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications J Am Soc Nephrol 9 1998 2344 2348 (Pubitemid 28543813)
13. M. Uchihara, N. Izumi, Y. Sakai, T. Yauchi, S. Miyake, and T. Sakai Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum level of interferon Nephron 80 1998 51 56 (Pubitemid 28434692)
14. S.K. Gupta, A.L. Pittenger, S.K. Swan, T.C. Marbury, E. Tobillo, and V. Batra Single-dose pharmakinetics and safety of pegylated interferon alpha 2b in patients with chronic renal dysfunction J Clin Pharmacol 42 2002 1109 1115
15. P. Glue, J.W. Fang, R. Rouzier-Panis, C. Raffanel, R. Sabo, and S.K. Gupta Pegylated interferon alpha 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group Clin Pharmacol Ther 68 2000 556 567
16. L. Rostaing Treatment of hepatitis C virus infection after renal transplantation: new insights Nephrol Dial Transplant 15 Suppl. 8 2000 74 76 (Pubitemid 32149515)
17. W.C. Lee, K.H. Shu, C.H. Cheng, M.J. Wu, C.H. Chen, and J.C. Lian Long term impact of hepatitis B, C virus infection on renal transplantation Am J Nephrol 21 2001 300 306
18. A. Bruchfeld, H. Wilczek, and C.G. Elinder Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation Transplantation 78 2004 745 750 (Pubitemid 39244740)
19. A. Aroldi, P. Lampertico, G. Montagnino, P. Passerini, M. Villa, and M.R. Campise Natural history of hepatitis B and C in renal allograft recipients Transplantation 79 2005 1132 1136 (Pubitemid 40664010)
20. J.M. Campistol, N. Esforzado, J. Martinez, L. Rosello, L. Veciana, and J. Modol Efficacy and tolerance of interferon alpha 2a in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre and post-renal transplantation assessment Nephrol Dial Transplant 14 1999 2704 2709 (Pubitemid 32208390)
21. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease Kidney Int Suppl 2008 S1 S99
22. F. Fabrizi, G. Dulai, V. Dixit, S. Bunnapradist, and P. Martin Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients Aliment Pharmacol Ther 18 2003 1071 1081 (Pubitemid 38021592)
23. M.W. Russo, C.D. Goldsweig, I.M. Jacobson, and R.S. Brown Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety Am J Gastroenterol 98 2003 1610 1615 (Pubitemid 36875356)
24. C.E. Gordon, K. Uhlig, J. Lau, H. Schmid, A.S. Levey, and J.B. Wong Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms Am J Kidney Dis 51 2008 263 277
25. A. Covic, I.D. Maftei, N.G. Mardare, F. Ionita-Radu, C. Totolici, and L. Tuta Analysis of safety and efficacy of pegalyted-interferon alpha 2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit J Nephrol 19 2006 794 801 (Pubitemid 46415986)
26. M.W. Russo, R. Ghalib, S. Sigal, and V. Joshi Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C Nephrol Dial Transplant 21 2006 437 443 (Pubitemid 43160000)
27. T.M. Chan, S.K. Ho, C.S. Tang, K.C. Tse, M.F. Lam, and K.N. Lai Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection Nephrology (Carlton) 12 2007 11 17
28. I. Sporea, A. Popescu, R. Sirli, O. Golea, C. Totolici, and M. Danila Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis World J Gastroenterol 12 2006 4191 4194 (Pubitemid 44376900)
29. B.E. Annicchiarico, and M. Siciliano Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C Aliment Pharmacol Ther 20 2004 123 124 (Pubitemid 38938726)
30. D.N. Amarapurkar, N.D. Patel, and A.L. Kirpalani Monotherapy with peginterferon alpha 2 b[12 kDa] for chronic hepatitis C infection in patients undergoing haemodialysis Trop Gastroenterol 28 2007 16 18
31. F. Fabrizi, V. Dixit, P. Messa, and P. Martin Pegylated interferon montherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials J Med Virol 82 2010 768 775
32. A. Bruchfeld, K. Lindhal, O. Reichard, T. Carlsson, and R. Schvarcz Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients J Viral Hepat 13 2006 316 321
33. R. van Leusen, R.P. Adang, R.A. de Vries, T.T. Cnossen, C.J. Konings, and S.W. Schalm Pegalyted interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C Nephrol Dial Transplant 23 2008 721 725 (Pubitemid 351767641)
34. D.H. Mousa, A.H. Abdalla, G. Al Shoail, M.H. Al Sulaiman, F.A. Al Hawas, and A.A. Al Khader Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C Transplant Proc 36 2004 1831 1834 (Pubitemid 39200440)
35. D. Carriero, F. Fabrizi, A.J. Uriel, J. Park, P. Martin, and D.T. Dieterich Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low dose ribavirin Int J Artif Organs 31 2008 295 302 (Pubitemid 351890659)
36. M. Rendina, A. Schena, N.M. Castellaneta, F. Losito, A.C. Amoruso, and G. Stallone The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant J Hepatol 46 2007 768 774 (Pubitemid 46529043)
37. G.L. Davis, and J.Y. Lau Factors predictive of a beneficial response to therapy of hepatitis C Hepatology 26 1997 122S 127S (Pubitemid 27388084)
38. T. Tokumoto, K. Tanabe, and N. Ishikawa Effects of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C Transplant Proc 31 1999 2887 2889 (Pubitemid 29525688)